Pharma: Other News To Note
Monday, December 10, 2012
Alfa Wassermann SpA, of Bologna, Italy, and Norgine BV, of Amsterdam, the Netherlands, received European marketing authorization for Xifaxan 550-mg (rifaximin-alpha)/Refero/Targaxan/Tixteller for hepatic encephalopathy, a neuropsychiatric condition that can occur with cirrhosis of the liver.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.